Regulatory T cells in multiple sclerosis and myasthenia gravis
Reads0
Chats0
TLDR
Several strategies of treatment which have been shown to be effective or are proposed as potential therapies to restore the function of various Treg subsets including Tr1, iTr35, nTregs, and iTregs appear promising for treating patients with MS or MG.Abstract:
Multiple sclerosis (MS) is a chronic debilitating disease of the central nervous system primarily mediated by T lymphocytes with specificity to neuronal antigens in genetically susceptible individuals. On the other hand, myasthenia gravis (MG) primarily involves destruction of the neuromuscular junction by antibodies specific to the acetylcholine receptor. Both autoimmune diseases are thought to result from loss of self-tolerance, which allows for the development and function of autoreactive lymphocytes. Although the mechanisms underlying compromised self-tolerance in these and other autoimmune diseases have not been fully elucidated, one possibility is numerical, functional, and/or migratory deficits in T regulatory cells (Tregs). Tregs are thought to play a critical role in the maintenance of peripheral immune tolerance. It is believed that Tregs function by suppressing the effector CD4+ T cell subsets that mediate autoimmune responses. Dysregulation of suppressive and migratory markers on Tregs have been linked to the pathogenesis of both MS and MG. For example, genetic abnormalities have been found in Treg suppressive markers CTLA-4 and CD25, while others have shown a decreased expression of FoxP3 and IL-10. Furthermore, elevated levels of pro-inflammatory cytokines such as IL-6, IL-17, and IFN-γ secreted by T effectors have been noted in MS and MG patients. This review provides several strategies of treatment which have been shown to be effective or are proposed as potential therapies to restore the function of various Treg subsets including Tr1, iTr35, nTregs, and iTregs. Strategies focusing on enhancing the Treg function find importance in cytokines TGF-β, IDO, interleukins 10, 27, and 35, and ligands Jagged-1 and OX40L. Likewise, strategies which affect Treg migration involve chemokines CCL17 and CXCL11. In pre-clinical animal models of experimental autoimmune encephalomyelitis (EAE) and experimental autoimmune myasthenia gravis (EAMG), several strategies have been shown to ameliorate the disease and thus appear promising for treating patients with MS or MG.read more
Citations
More filters
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis
Ashley Beecham,Nikolaos A. Patsopoulos,Nikolaos A. Patsopoulos,Dionysia K. Xifara,Mary F. Davis,Anu Kemppinen,Chris Cotsapas,Chris Cotsapas,Tejas S. Shah,Chris C. A. Spencer,David R. Booth,An Goris,Annette Bang Oturai,Janna Saarela,Bertrand Fontaine,Bernhard Hemmer,C. Martin,Frauke Zipp,Sandra D'Alfonso,Filippo Martinelli-Boneschi,Bruce V. Taylor,Hanne F. Harbo,Ingrid Kockum,Jan Hillert,Tomas Olsson,Maria Ban,Jorge R. Oksenberg,Rogier Q. Hintzen,Lisa F. Barcellos,Lisa F. Barcellos,Lisa F. Barcellos,Cristina Agliardi,Lars Alfredsson,Mehdi Alizadeh,Carl A. Anderson,Robert Andrews,Helle Bach Søndergaard,Amie Baker,Gavin Band,Sergio E. Baranzini,Nadia Barizzone,Jeffrey C. Barrett,Céline Bellenguez,Laura Bergamaschi,Luisa Bernardinelli,Achim Berthele,Viola Biberacher,Thomas M.C. Binder,Hannah Blackburn,Izaura Lima Bomfim,Paola Brambilla,Simon Broadley,Bruno Brochet,Lou Brundin,Dorothea Buck,Helmut Butzkueven,Helmut Butzkueven,Stacy J. Caillier,William Camu,Wassila Carpentier,Paola Cavalla,Elisabeth Gulowsen Celius,Irene Coman,Giancarlo Comi,Lucia Corrado,Leentje Cosemans,Isabelle Cournu-Rebeix,Bruce A.C. Cree,Daniele Cusi,Vincent Damotte,Gilles Defer,Silvia Delgado,Panos Deloukas,Alessia Di Sapio,Alexander T. Dilthey,Peter Donnelly,Bénédicte Dubois,Martin Duddy,Sarah Edkins,Irina Elovaara,Federica Esposito,Nikos Evangelou,Barnaby Fiddes,Judith Field,Andre Franke,Colin Freeman,Irene Y. Frohlich,Daniela Galimberti,Christian Gieger,Pierre-Antoine Gourraud,Christiane Graetz,Andrew Graham,Verena Grummel,Clara Guaschino,Athena Hadjixenofontos,Hakon Hakonarson,Christopher Halfpenny,Gillian L Hall,Per Hall,Anders Hamsten,James Harley,Timothy Harrower,Clive Hawkins,Garrett Hellenthal,Charles Hillier,Jeremy Hobart,M.-M. Hoshi,Sarah E. Hunt,Maja Jagodic,Ilijas Jelcic,Ilijas Jelcic,Angela Jochim,B. E. Kendall,Allan G. Kermode,Allan G. Kermode,Trevor J. Kilpatrick,Keijo Koivisto,Ioanna Konidari,Thomas Korn,Helena C. Kronsbein,Cordelia Langford,Malin Larsson,Mark Lathrop,Mark Lathrop,Christine Lebrun-Frenay,Jeannette Lechner-Scott,Michelle Lee,Maurizio Leone,Virpi Leppa,Giuseppe Liberatore,Benedicte A. Lie,Christina M. Lill,Christina M. Lill,Magdalena Lindén,Jenny Link,Felix Luessi,Jan Lycke,Fabio Macciardi,Fabio Macciardi,Satu Männistö,Clara P. Manrique,Roland Martin,Roland Martin,Vittorio Martinelli,Deborah F. Mason,Gordon Mazibrada,Cristin McCabe,Inger Lise Mero,Julia Y Mescheriakova,Loukas Moutsianas,Kjell-Morten Myhr,Guy Nagels,Richard Nicholas,Petra Nilsson,Fredrik Piehl,Matti Pirinen,Siân Price,Hong Quach,Mauri Reunanen,Wim Robberecht,Neil Robertson,Mariaemma Rodegher,David Rog,Marco Salvetti,Nathalie Schnetz-Boutaud,Finn Sellebjerg,Rebecca C. Selter,Catherine Schaefer,Sandip Shaunak,Ling Shen,Simon Shields,Volker Siffrin,Mark Slee,Per Soelberg Sørensen,Melissa Sorosina,Mireia Sospedra,Mireia Sospedra,Anne Spurkland,Amy Strange,Emilie Sundqvist,Vincent Thijs,J W Thorpe,Anna Ticca,Pentti J. Tienari,Cornelia M. van Duijn,Elizabeth Visser,Steve Vucic,Helga Westerlind,James S. Wiley,Alastair Wilkins,James F. Wilson,Juliane Winkelmann,John Zajicek,Eva Zindler,Jonathan L. Haines,Margaret A. Pericak-Vance,Adrian J. Ivinson,Graeme J. Stewart,David A. Hafler,David A. Hafler,Stephen L. Hauser,Alastair Compston,Gil McVean,Philip L. De Jager,Philip L. De Jager,Stephen Sawcer,Jacob L. McCauley +206 more
TL;DR: Using the ImmunoChip custom genotyping array, this article analyzed 14,498 subjects with multiple sclerosis and 24,091 healthy controls for 161,311 autosomal variants and identified 135 potentially associated regions (P < 1.0 × 10(-4)).
Journal ArticleDOI
Tregs: Where We Are and What Comes Next?
Hai Zhao,Xuelian Liao,Yan Kang +2 more
TL;DR: This work discusses the expanding family of regulatory lymphocytes briefly and tries to interpret how fork-head box P3 (Foxp3), a master regulator of the regulatory pathway in the development and function of regulatory T cells, functions.
Journal ArticleDOI
A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity.
TL;DR: The role of various co-stimulatory and co-inhibitory receptors in Treg biology and immune homeostasis, autoimmunity, and anti-tumor immunity is reviewed and the autoimmune adverse events arising upon targeting these co-signaling receptors are discussed.
Journal ArticleDOI
Treg cells in autoimmunity: from identification to Treg-based therapies
TL;DR: The traditional view that Treg cells become necessarily pathogenic by gaining effector functions was challenged by recent findings and supports the notion of Treg cell lineage plasticity.
Journal ArticleDOI
Treg cells in health and autoimmune diseases: New insights from single cell analysis.
TL;DR: Based on new technological advances a new understanding of the heterogeneity of different Treg cell populations in the lymphoid and non-lymphoid tissue has evolved, and it is learned that Treg cells from various tissue can be identified by a specific transcriptomic and epigenetic signature.
References
More filters
Journal ArticleDOI
Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation.
TL;DR: It is reported that the Treg cells that control intestinal inflammation express the same phenotype (CD25+CD45RBlowCD4+) as those that control autoimmunity, suggesting that Treg cell function contributes to the immune suppression characteristic of CTLA-4 signaling.
Journal ArticleDOI
Immunologic Self-Tolerance Maintained by Cd25+Cd4+Regulatory T Cells Constitutively Expressing Cytotoxic T Lymphocyte–Associated Antigen 4
Takeshi Takahashi,Tomoyuki Tagami,Sayuri Yamazaki,Toshimitsu Uede,Jun Shimizu,Noriko Sakaguchi,Tak W. Mak,Shimon Sakaguchi +7 more
TL;DR: Interference with this role of CTLA-4 suffices to elicit autoimmune disease in otherwise normal animals, presumably through affecting CD25+CD4+ T cell–mediated control of self-reactive T cells.
Journal ArticleDOI
The inhibitory cytokine IL-35 contributes to regulatory T-cell function
Lauren W. Collison,Creg J. Workman,Timothy T. Kuo,Kelli L. Boyd,Yao Wang,Kate M. Vignali,Richard L. Cross,David Sehy,Richard S. Blumberg,Dario A. A. Vignali +9 more
TL;DR: IL-35 is identified as a novel inhibitory cytokine that may be specifically produced by Treg cells and is required for maximal suppressive activity.
Journal ArticleDOI
Loss of Functional Suppression by CD4+CD25+ Regulatory T Cells in Patients with Multiple Sclerosis
TL;DR: A significant decrease in the effector function of CD4+CD25hi regulatory T cells from peripheral blood of patients with MS as compared with healthy donors is reported.
Journal ArticleDOI
The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights
TL;DR: A greater understanding is required of the mechanisms by which glucocorticoids exert their anti-inflammatory and immunosuppressive actions, and recent research is shedding new light on some of these mechanisms and has produced some surprising new findings.